Fluorescence-guided surgery allows for more complete resection of pancreatic cancer, resulting in longer disease-free survival compared with standard surgery in orthotopic mouse models

Journal of the American College of Surgeons

Volumn 215, Issue 1, 2012, Pages 126-135

  Metildi, Cristina A ^a   Kaushal, Sharmeela ^a   Hardamon, Chanae R ^a   Snyder, Cynthia S ^a   Pu, Minya ^a   Messer, Karen S ^a   Talamini, Mark A ^a   Hoffman, Robert M ^a,b   Bouvet, Michael ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ANTICANCER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GEMCITABINE; RED FLUORESCENT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPSY; BRIGHT LIGHT SURGERY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FLUORESCENCE; FLUORESCENCE GUIDED SURGERY; INTERMETHOD COMPARISON; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; SURGICAL TECHNIQUE; TREATMENT OUTCOME; TUMOR GROWTH; TUMOR VOLUME; WHOLE BODY IMAGING;

ANIMALS; DISEASE MODELS, ANIMAL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LUMINESCENT PROTEINS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PANCREATECTOMY; PANCREATIC NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 84862979798     PISSN: 10727515     EISSN: 18791190     Source Type: Journal    
DOI: 10.1016/j.jamcollsurg.2012.02.021     Document Type: Article

References (36)

1. Sener SF, Fremgen A, Menck HR, Winchester DP. Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database. J Am Coll Surg 1999;189:1-7. (Pubitemid 29307735)
2. Adham M, Jaeck D, Le Borgne J, et al. Long-term survival (5-20 years) after pancreatectomy for pancreatic ductal adenocarcinoma: a series of 30 patients collected from 3 institutions. Pancreas 2008;37:352-357.
3. Cartwright T, Richards DA, Boehm KA. Cancer of the pancreas: are we making progress? A review of studies in the USOncology Research Network. Cancer Control 2008;15:308-313.
4. Conlon KC, Klimstra DS, Brennan MF. Long-term survival after curative resection for pancreatic ductal adenocarcinoma. Clinicopathologic analysis of 5-year survivors. Ann Surg 1996; 223:273-279. (Pubitemid 26086718)
5. Di Marco M, Di Cicilia R, Macchini M, et al. Metastatic pancreatic cancer: is gemcitabine still the best standard treatment? (Review) Oncol Rep 2010;23:1183-1192.
6. Shimada K, Sakamoto Y, Nara S, et al. Analysis of 5-year survivors after a macroscopic curative pancreatectomy for invasive ductal adenocarcinoma.World J Surg 2010;34:1908-1915.
7. Yeo CJ, Cameron JL, Lillemoe KD, et al. Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients. Ann Surg 1995;221:721-731; discussion 731-733.
8. Jiang T, Olson ES, Nguyen QT, et al. Tumor imaging by means of proteolytic activation of cell-penetrating peptides. Proc Natl Acad Sci U S A 2004;101:17867-17872. (Pubitemid 40051978)
9. Kennedy MD, Jallad KN, Thompson DH, et al. Optical imaging of metastatic tumors using a folate-targeted fluorescent probe. J Biomed Opt 2003;8:636-641.
10. Kishimoto H, Kojima T, Watanabe Y, et al. In vivo imaging of lymph node metastasis with telomerase-specific replication-selective adenovirus. Nat Med 2006;12:1213-1219. (Pubitemid 44527360)
11. Olson ES, Aguilera TA, Jiang T, et al. In vivo characterization of activatable cell penetrating peptides for targeting protease activity in cancer. Integr Biol (Camb) 2009;1:382-393.
12. Kaushal S, McElroy MK, Luiken GA, et al. Fluorophore-conjugated anti-CEA antibody for the intraoperative imaging of pancreatic and colorectal cancer. J Gastrointest Surg 2008;12: 1938-1950.
13. Kishimoto H, Zhao M, Hayashi K, et al. In vivo internal tumor illumination by telomerase-dependent adenoviral GFP for precise surgical navigation. Proc Natl Acad Sci U S A 2009;106: 14514-14517.
14. McElroy M, Kaushal S, Luiken GA, et al. Imaging of primary and metastatic pancreatic cancer using a fluorophore-conjugated anti-CA19-9 antibody for surgical navigation. World J Surg 2008;32:1057-1066.
15. Nguyen QT, Olson ES, Aguilera TA, et al. Surgery with molecular fluorescence imaging using activatable cell-penetrating peptides decreases residual cancer and improves survival. Proc Natl Acad Sci U S A 2010;107:4317-4322.
16. Tran Cao HS, Kaushal S, Lee C, et al. Fluorescence laparoscopy imaging of pancreatic tumor progression in an orthotopic mouse model. Surg Endosc 2011;25:48-54.
17. Tran Cao HS, Kaushal S, Menen RS, et al. Submillimeter-resolution fluorescence laparoscopy of pancreatic cancer in a carcinomatosis mouse model visualizes metastases not seen with standard laparoscopy. J Laparoendosc Adv Surg Tech A 2011; 21:485-489.
18. Tran Cao HS, Kaushal S, Metildi CA, et al. Fluorophore-conjugated anti-CEA antibody improves accuracy of staging laparoscopy in a mouse model of pancreatic cancer. Ann Surg Oncol 2011;18(Suppl 1):S40.
19. van Dam GM, Themelis G, Crane LM, et al. Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-alpha targeting: first in-human results. NatMed 2011; 17:1315-1319.
20. Bouvet M, Hoffman RM. Glowing tumors make for better detection and resection. Sci Transl Med 2011;3:110fs10.
21. Katz MH, Takimoto S, Spivack D, et al. A novel red fluorescent protein orthotopic pancreatic cancer model for the preclinical evaluation of chemotherapeutics. J Surg Res 2003;113:151-160. (Pubitemid 36999806)
22. Brookmeyer R, Crowley J. A confidence interval for the median survival time. Biometrics 1982;38:29-41.
23. Loos M, Kleeff J, Friess H, Buchler MW. Surgical treatment of pancreatic cancer. Ann N Y Acad Sci 2008;1138:169-180.
24. Garcea G, Dennison AR, Pattenden CJ, et al. Survival following curative resection for pancreatic ductal adenocarcinoma. A systematic review of the literature. JOP 2008;9:99-132. (Pubitemid 351611725)
25. Benassai G, Mastrorilli M, Quarto G, et al. Factors influencing survival after resection for ductal adenocarcinoma of the head of the pancreas. J Surg Oncol 2000;73:212-218. (Pubitemid 30238413)
26. Chen JW, Bhandari M, Astill DS, et al. Predicting patient survival after pancreaticoduodenectomy for malignancy: histopathological criteria based on perineural infiltration and lymphovascular invasion. HPB (Oxford) 2010;12:101-108.
27. Sperti C, Pasquali C, Piccoli A, Pedrazzoli S. Recurrence after resection for ductal adenocarcinoma of the pancreas. World J Surg 1997;21:195-200. (Pubitemid 27053441)
28. Jamieson NB, Foulis AK, Oien KA, et al. Positive mobilization margins alone do not influence survival following pancreaticoduodenectomy for pancreatic ductal adenocarcinoma. Ann Surg 2010;251:1003-1010.
29. Mannell A, van Heerden JA, Weiland LH, Ilstrup DM. Factors influencing survival after resection for ductal adenocarcinoma of the pancreas. Ann Surg 1986;203:403-407. (Pubitemid 16056763)
30. Matsuno S, Sato T. Surgical treatment for carcinoma of the pancreas. Experience in 272 patients. Am J Surg 1986;152:499-504.
31. Sommerville CA, Limongelli P, Pai M, et al. Survival analysis after pancreatic resection for ampullary and pancreatic head carcinoma: an analysis of clinicopathological factors. J Surg Oncol 2009;100:651-656.
32. Troyan SL, Kianzad V, Gibbs-Strauss SL, et al. The FLARE intraoperative near-infrared fluorescence imaging system: a first-in-human clinical trial in breast cancer sentinel lymph node mapping. Ann Surg Oncol 2009;16:2943-2952.
33. Stummer W, Pichlmeier U, Meinel T, et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 2006;7:392-401.
34. Stiles BM, Adusumilli PS, Bhargava A, et al. Minimally invasive localization of oncolytic herpes simplex viral therapy of metastatic pleural cancer. Cancer Gene Ther 2006;13:53-64. (Pubitemid 41816349)
35. Kishimoto H, Aki R, Urata Y, et al. Tumor-selective, adenoviral-mediated GFP genetic labeling of human cancer in the live mouse reports future recurrence after resection. Cell Cycle 2011; 10:2737-2741.
36. Kishimoto H, Urata Y, Tanaka N, et al. Selective metastatic tumor labeling with green fluorescent protein and killing by systemic administration of telomerase-dependent adenoviruses. Mol Cancer Ther 2009;8:3001-3008.